Double-Blind Trial of Aspirin in Primary Prevention of Myocardial Infarction in Patients With Stable Chronic Angina Pectoris - SAPAT
This was a prospective, double-blind, randomized trial of low-dose aspirin as primary prevention for myocardial infarction (MI) among patients with chronic angina.
The addition of low-dose aspirin to sotalol may be associated with a decreased incidence of MI.
Patients Enrolled: 2,035
Mean Follow Up: 50 months
Mean Patient Age: Mean of 67
History of exertional chest pain for at least one month and age 30-80
- Patients already on aspirin, anticoagulants, verapamil, or nonsteroidal anti-inflammatory drug
- Patients on more than hydrochlorothiazide 50 mg, bendroflumethiazide 5 mg, or furosemide 40 mg
- Treatment with class I antiarrhythmic
- Heart rate <55 per minute
- History of MI
- Type II or III AV block
- Symptoms of obstructive lung disease
- Active peptic ulcer disease
- Hypersensitivity to aspirin
- Juvenile diabetes
- Uncontrolled late-onset diabetes
First occurrence of nonfatal, in-hospital MI, or sudden death
Vascular events (first occurrence of MI, stroke, or vascular death), vascular death, all-cause mortality, or stroke
Patients were randomized to aspirin 75 mg daily (n=1,009) or placebo (n=1,026)
Sotalol at mean dose of 160 mg daily
- Addition of aspirin 75 mg daily was associated with 34% reduction in primary outcome of MI or sudden death (8% vs. 12%, p=0.003).
- Addition of aspirin was associated with a 32% reduction in vascular events compared with placebo (10.7% vs. 15.7%, p<0.001).
- There was no significant difference in the incidence of major bleeding.
Among patients with chronic angina, the addition of low-dose aspirin in addition to sotalol was associated with a significant reduction in MI and death without an increase in major bleeding compared with sotalol alone.
Juul-Moller S, Edvardsson N, Jahnmatz B, Rosen A, Sorensen S, Omblus R. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet 1992;340:1421-5.
Clinical Topics: Prevention
Keywords: Myocardial Infarction, Platelet Aggregation Inhibitors, Death, Sudden, Coronary Disease, Sotalol, Hemorrhage, Primary Prevention
< Back to Listings